Non-invasive detection of response to a targeted therapy
AssigneeThe Johns Hopkins University
InventorsVictor E. Velculescu, Jillian A. Phallen, Alessandro Leal, Hatim Husain
Life of this patent
Estimating the term…
Abstract
Provided herein are method of determining the efficacy of targeted therapy in a subject by detecting changes in levels of cell-free tumor load (cfTL). In some aspects, the efficacy of targeted therapy is determined a very short time after the targeted therapy is administered. Also provided herein are method of determining resistance to a targeted therapy in a subject by detecting changes in levels of cell-free tumor load (cfTL).
Claims27
A method of determining the efficacy of a targeted therapy in a subject having cancer, comprising:
- detecting a first cell-free tumor load (cfTL) in a biological sample isolated from the subject at a first time point;
- detecting a second cfTL in a biological sample obtained from the subject at a second time point, wherein the subject has received at least one dose of the targeted therapy between the first time point and the second time point;
- and
- identifying the targeted therapy as being effective in the subject when the subject exhibits a second cfTL that is reduced as compared to the first cfTL.
(canceled)
14-15. (canceled)
(canceled)
(canceled)
24-25. (canceled)
A method of determining response to a targeted therapy in a subject having cancer, comprising:
- detecting a first level of at least one genetic alteration in circulating tumor DNA (ctDNA) in a biological sample isolated from the subject at a first time point;
- detecting a second level of the at least one genetic alteration in circulating tumor DNA (ctDNA) in a biological sample obtained from the subject at a second time point, wherein the subject has received at least one dose of the targeted therapy between the first time point and the second time point;
- and
- identifying the subject as responding to the targeted therapy when the second level of the at least one genetic alteration is substantially increased as compared to the first level of the at least one genetic alteration.
27-28. (canceled)
A method of determining poor efficacy of a targeted therapy in a subject having cancer, comprising:
- detecting a first cell-free tumor load (cfTL) in a biological sample isolated from the subject at a first time point;
- detecting a second cfTL in a biological sample obtained from the subject at a second time point, wherein the subject has received at least one dose of the targeted therapy between the first time point and the second time point;
- and
- identifying the targeted therapy as having poor efficacy in the subject when the subject exhibits a second cfTL that is not substantially reduced as compared to the first cfTL.
30-34. (canceled)
Dependencies are inferred from the claim text.